People with advanced cancer who communicated their symptoms weekly using an electronic survey had about a one-third better physical function and over a 15% better control of their symptoms compared to those who were evaluated less frequently via in-person clinical visits, according to findings from a multi-state study conducted at 52 community cancer clinics.
Researchers from the Parker Institute for Cancer Immunotherapy network identified certain patients with pancreatic cancer who may be more likely to benefit from combination treatment regimens consisting of immunotherapy and chemotherapy.
Positive data from a pivotal phase II/III trial for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (QUILT 3032) and phase II trial in advanced pancreatic cancer (QUILT 88) were announced at the 2022 ASCO annual meeting.
Data from the phase III PARADIGM clinical trial of Vectibix (panitumumab) in Japanese patients with previously untreated unresectable wild-type RAS metastatic colorectal cancer were featured during the plenary session of the 2022 ASCO annual meeting.
Racial and ethnic minorities diagnosed with advanced liver cancer have a lower chance of receiving immunotherapy, the most effective treatment for patients with the disease, according to a study led by Cedars-Sinai Cancer investigators.
Researchers at the American Cancer Society found that the number of women in the U.S. who reported having a recent (in the past year) breast cancer or cervical cancer screening dropped by 2.13 million (6%) and 4.47 million (11%) respectively in 2020 compared to 2018.
Researchers at the American Cancer Society found that perceptions of electronic or e-cigarettes as being “more harmful” than cigarettes by adults in the United States more than doubled between 2019-2020 and perceptions of e-cigarettes as “less harmful” declined between 2018-2020.
FDA granted Orphan Drug Designation to stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer.
The Parker Institute for Cancer Immunotherapy and National Resilience Inc. announced a five-year strategic alliance to develop next-generation cancer therapies.
Dana-Farber Cancer Institute, Gustave Roussy, and L’Institut Servier signed a cooperation agreement to foster collaboration among oncology researchers.
